Trabectedin mechanism of action: what's new?

Area of Science:

• Pharmacology and Molecular Biology
• Cancer Biology
• Immunology

Background:

• Trabectedin is a tetrahydroisoquinoline compound with DNA-binding properties.
• Its antitumor effects involve direct cytotoxicity and modulation of the tumor microenvironment.

Purpose of the Study:

• To elucidate the mechanisms of trabectedin's antitumor activity.
• To investigate its effects on cancer cells and the tumor microenvironment.
• To explore its therapeutic potential in various cancers.

Main Methods:

• DNA binding analysis at the N2 of guanine.
• Assessment of transcription regulation.
• Evaluation of cell cycle arrest and cell death induction.
• Analysis of homologous recombination deficiency impact.
• Investigation of immunomodulatory effects on monocytes and macrophages.
• Measurement of proinflammatory and angiogenic mediator production.

Main Results:

• Trabectedin induces gene- and promoter-specific DNA damage and transcription alterations.
• It causes p53-independent cell cycle arrest and cell death, particularly in homologous recombination-deficient cells (e.g., BRCA1/2 mutated).
• Trabectedin exhibits selective cytotoxicity towards monocytes and tumor-associated macrophages.
• It suppresses proinflammatory and angiogenic factors, altering the tumor microenvironment.

Conclusions:

• Trabectedin possesses dual antitumor mechanisms: direct cancer cell killing and favorable tumor microenvironment modification.
• Its efficacy is potentiated in homologous recombination-deficient cancers.
• Trabectedin's immunomodulatory and anti-angiogenic properties contribute significantly to its overall therapeutic effect.
• It represents a promising therapeutic option for various cancers, potentially in combination therapies.